SPYH:F:F-SSgA SPDR ETFs Europe II Public Limited Company - SPDR MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 218.35

Change

+2.75 (+1.28)%

Market Cap

USD 0.64B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

-0.34 (-1.26%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.70 (-1.37%)

USD 115.04B
FRCJ:F UBS MSCI Japan Socially Respon..

-0.32 (-1.48%)

USD 83.57B
SXR8:F iShares Core S&P 500 UCITS ETF..

-0.94 (-0.18%)

USD 80.45B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.75 (-1.37%)

USD 76.57B
EUNL:F iShares Core MSCI World UCITS ..

-0.01 (-0.01%)

USD 72.04B
SXRZ:F iShares VII PLC - iShares Nikk..

-3.60 (-1.55%)

USD 58.19B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.20 (-1.31%)

USD 56.18B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.09 (-0.10%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

-0.08 (-0.09%)

USD 51.63B

ETFs Containing SPYH:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.93% 76% C+ 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.93% 74% C 65% D
Trailing 12 Months  
Capital Gain 7.99% 54% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.99% 52% F 55% F
Trailing 5 Years  
Capital Gain 64.57% 84% B 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.57% 84% B 65% D
Average Annual (5 Year Horizon)  
Capital Gain 8.63% 78% C+ 73% C
Dividend Return 8.63% 77% C+ 67% D+
Total Return N/A 66% D+ 94% A
Risk Return Profile  
Volatility (Standard Deviation) 8.52% 65% D 85% B
Risk Adjusted Return 101.25% 99% N/A 97% N/A
Market Capitalization 0.64B 66% D+ 53% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike